|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.08/-1.23
|
企业价值
218.07M
|
资产负债 |
每股账面净值
4.44
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/29 23:04 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, isa subclass monoclonal antibody that selectively targets amyloid-beta oligomers. |